Article Text

Download PDFPDF

1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies
  1. Jean-Philippe Guégan1,
  2. Kohei Shitara2,
  3. Sophie Cousin3,
  4. Shota Fukuoka4,
  5. Jean-Philippe Metges5,
  6. Antoine Adenis6,
  7. Carlos Gomez-Roca7,
  8. Philippe Cassier8,
  9. Antoine Hollebecque9,
  10. Lola-Jade Palmieri10,
  11. Shohei Koyama11,
  12. Hiroyoshi Nishikawa12,
  13. Alban Bessede13 and
  14. Antoine Italiano3
  1. 1Explicyte Immuno-Oncology, Bordeaux, Gironde, France
  2. 2National Cancer Hospital East, Chiba, Japan
  3. 3Institut Bergonié, Bordeaux, France
  4. 4Cancer Institute Hospital, Tokyo, Japan
  5. 5Hopital Augustin Morvan, Brest, France
  6. 6Institut du Cancer de Montpellier, Montpellier, France
  7. 7Institut Universitaire du Cancer, Oncopole, Toulouse, France
  8. 8Centre Leon Berard, Lyon, France
  9. 9Gustave Roussy Cancer Campus, Antony, France
  10. 10Institut Bergonié, Bordeaux, Gironde, France
  11. 11National Cancer Center, Tokyo, Japan
  12. 12National Cancer Center, Kashiwa, Chiba, Japan
  13. 13Explicyte, Bordeaux, France


Background The REGOMUNE and REGONIVO studies showed promising antitumor activity when anti-PD-1/PDL1 antibodies were paired with the multikinase inhibitor regorafenib in the treatment of Advanced Gastric Cancer (AGC).1 2 This study aims to uncover the factors that contribute to primary resistance against this therapeutic strategy.

Methods Tumor samples were collected from patients with AGC enrolled in the REGOMUNE (NCT03475953) and REGONIVO (NCT03406871) studies. We spatially profiled the expression of >18,000 protein-coding genes across six tumors (three responders and three progressors) using the GeoMx whole-transcriptome atlas (WTA) assay. ROIs were drawn to analyze the expression of the WTA gene panel within the tumor region. Each tumor ROI was further segmented in 3 AOIs (to analyze the ‘Tumor’ (PanCK+ CD45-), ‘Immune’ (CD45+) and ‘Stroma’ (PanCK-) compartments. To visualize the differences in immune cell abundances between responders and non-responders, we developed two multiplex IHC panels that enabled simultaneous detection of CD8+ T cells, monocytes, activated dendritic cells M2 macrophages, S100A10, AnxA2, and tumor cells in all the patients with available tumor material from the REGOMUNE and from the REGONIVO studies (n=45). To detect potential peripheral biomarkers associated with resistance to regorafenib plus ICI, we implemented a proteomics analysis of plasma samples by using the Olink technology as previously described.3

Results Comparative spatial transcriptomic analysis of the tumor compartment revealed a strong upregulation of S100A10, a member of the S100 protein family, alongside its ligand, Annexin A2 in non-responder patients. Notably, these two elements form a heterotetrameric complex playing a key role in regulating tumor cell proliferation, angiogenesis and macrophage infiltration. The tumor compartment of non-responders was significantly enriched in several oncogenic hallmark pathways including TGF beta signaling. Deconvolution analysis of the Immune cell compartment revealed a significant enrichment in macrophages in the non-responder group. By using multiplex IF, we confirmed that M2 macrophages defined as CD68+ HLA-DR- was the immune cell population most differentially represented between responders and non-responders (median PFS and OS 1.8 and 4.3 months versus 4.26 and 13.4 months respectively; P = 0.006 and P = 0.004). Higher S100A10-expressing tumor cells correlated with worse PFS and OS. Plasma studies showed cytokines like CSF-1, IL-4, and TWEAK, linked with macrophage infiltration, were prevalent in patients with unfavorable outcomes.

Conclusions This in-depth exploratory analysis of blood and tumor samples indicates that elimination and reprogramming of tumor-associated macrophages may be a breakthrough to efficiently induce potent anti-tumor immunity in patient with ADG.


  1. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20;38(18):2053–2061.

  2. Cousin et al. REGOMUNE: a phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 4060–4060.

  3. Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021 Nov;32(11):1381–1390.

Ethics Approval Both REGOMUNE and REGONIVO studies get ethics approval [1,2]. All participants gave informed consent before taking part.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.